Stock listing
OTC:BBAGF BB Biotech AG Stock
US listing (OTC) of BB Biotech AG · home listing SIX Swiss:BION
Follow BB Biotech AG into a list and get an email when it puts out news.
Home listing price · SIX:BION
52.60 CHF -0.20 (-0.4%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, SIX:BION
- Day range
- 52.40 – 53.20 CHFNov 20, 2026
- Volume
- 85,517 sharesNov 20, 2026
- Market cap
- 2.90B CHFAt the close on Nov 20, 2026 · price × 55.15M shares outstanding
- 52-week range
- 41.05 – 57.00 CHFLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 4.10M CHFMedian day 73,928 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| SIX Swiss:BION · Home | 52.60 CHF | -0.20 (-0.4%) | 85,517 | 52.50 | 53.20 | 52.40 | 52.80 | Close on Nov 20, 2026 |
| Xetra:BBZA | €57.30 EUR | +0.20 (+0.4%) | 5,508 | €56.80 | €57.50 | €56.70 | €57.10 | Close on Nov 20, 2026 |
| Frankfurt:BBZA | €55.60 EUR | -1.30 (-2.3%) | 95 | €55.60 | €55.60 | €55.60 | €56.90 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SIX:BION · CHF, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 52.60 | -0.20 | -0.4% | 52.50 | 53.20 | 52.40 | 85,517 | |
| 52.80 | 0.00 | 0.0% | 52.70 | 53.60 | 52.70 | 45,532 | |
| 52.80 | -1.30 | -2.4% | 53.50 | 53.60 | 52.60 | 50,853 | |
| 54.10 | +0.10 | +0.2% | 54.10 | 54.90 | 53.80 | 56,450 | |
| 54.00 | -0.80 | -1.5% | 54.70 | 55.00 | 53.80 | 58,030 | |
| 54.80 | -0.10 | -0.2% | 55.20 | 55.40 | 54.20 | 66,092 | |
| 54.90 | +1.10 | +2.0% | 54.80 | 55.20 | 54.40 | 90,736 | |
| 53.80 | +0.30 | +0.6% | 53.70 | 54.60 | 53.70 | 81,231 | |
| 53.50 | +1.90 | +3.7% | 51.60 | 53.70 | 51.60 | 70,512 | |
| 51.60 | -0.30 | -0.6% | 51.00 | 51.90 | 50.30 | 79,766 | |
| 51.90 | +0.10 | +0.2% | 52.40 | 53.30 | 51.70 | 112,262 | |
| 51.80 | +0.20 | +0.4% | 51.30 | 52.40 | 51.00 | 80,046 | |
| 51.60 | +0.90 | +1.8% | 50.90 | 51.80 | 50.40 | 41,937 | |
| 50.70 | -0.60 | -1.2% | 51.20 | 51.60 | 50.70 | 63,219 | |
| 51.30 | +0.10 | +0.2% | 51.00 | 52.10 | 50.80 | 70,194 | |
| 51.20 | +1.00 | +2.0% | 50.20 | 51.80 | 50.20 | 92,482 | |
| 50.20 | -0.10 | -0.2% | 50.30 | 50.60 | 49.55 | 246,871 | |
| 50.30 | +0.90 | +1.8% | 49.10 | 50.40 | 49.10 | 38,625 | |
| 49.40 | +0.70 | +1.4% | 48.85 | 50.00 | 48.85 | 63,914 | |
| 48.70 | -1.30 | -2.6% | 49.90 | 50.00 | 48.70 | 87,948 | |
| 50.00 | -0.40 | -0.8% | 50.20 | 50.60 | 49.50 | 69,402 | |
| 50.40 | +0.20 | +0.4% | 50.30 | 50.70 | 50.00 | 74,060 | |
| 50.20 | +1.55 | +3.2% | 48.65 | 50.50 | 48.55 | 79,341 | |
| 48.65 | +0.50 | +1.0% | 48.00 | 48.65 | 47.80 | 57,173 | |
| 48.15 | -1.35 | -2.7% | 49.50 | 49.50 | 48.10 | 63,070 | |
| 49.50 | +0.75 | +1.5% | 48.35 | 49.50 | 48.35 | 76,925 | |
| 48.75 | -0.15 | -0.3% | 48.30 | 49.30 | 48.20 | 90,673 | |
| 48.90 | -0.60 | -1.2% | 49.40 | 49.70 | 48.85 | 56,877 | |
| 49.50 | +0.35 | +0.7% | 49.20 | 49.90 | 49.20 | 68,495 | |
| 49.15 | +1.35 | +2.8% | 48.20 | 49.15 | 48.20 | 91,994 | |
| 47.80 | -2.20 | -4.4% | 49.50 | 49.50 | 47.60 | 148,695 | |
| 50.00 | +0.35 | +0.7% | 49.00 | 50.00 | 49.00 | 94,608 | |
| 49.65 | +0.10 | +0.2% | 49.95 | 50.40 | 48.80 | 77,709 | |
| 49.55 | -0.75 | -1.5% | 50.00 | 50.90 | 49.25 | 73,795 | |
| 50.30 | -0.60 | -1.2% | 50.50 | 50.60 | 50.00 | 89,976 | |
| 50.90 | -1.00 | -1.9% | 51.50 | 51.80 | 50.70 | 86,534 | |
| 51.90 | +0.70 | +1.4% | 50.60 | 51.90 | 50.60 | 57,889 | |
| 51.20 | -0.20 | -0.4% | 51.40 | 51.80 | 50.90 | 34,219 | |
| 51.40 | +0.30 | +0.6% | 51.30 | 51.40 | 50.80 | 52,385 | |
| 51.10 | -0.10 | -0.2% | 51.30 | 51.60 | 50.90 | 66,684 | |
| 51.20 | -0.30 | -0.6% | 51.30 | 51.50 | 50.90 | 49,332 | |
| 51.50 | -0.70 | -1.3% | 52.30 | 52.50 | 51.20 | 92,709 | |
| 52.20 | +0.40 | +0.8% | 51.60 | 52.30 | 51.30 | 61,806 | |
| 51.80 | -0.50 | -1.0% | 52.10 | 52.20 | 51.50 | 44,832 | |
| 52.30 | +0.10 | +0.2% | 52.80 | 52.80 | 51.80 | 216,260 | |
| 52.20 | +0.50 | +1.0% | 52.20 | 52.80 | 52.00 | 127,986 | |
| 51.70 | -0.10 | -0.2% | 51.80 | 52.00 | 51.40 | 53,631 | |
| 51.80 | -0.60 | -1.1% | 52.20 | 52.70 | 51.30 | 73,474 | |
| 52.40 | -0.10 | -0.2% | 52.50 | 53.00 | 52.30 | 46,645 | |
| 52.50 | -0.30 | -0.6% | 52.60 | 53.30 | 52.20 | 82,317 | |
| 52.80 | -1.00 | -1.9% | 53.80 | 53.90 | 52.80 | 56,652 | |
| 53.80 | -0.10 | -0.2% | 53.70 | 54.10 | 53.50 | 43,109 | |
| 53.90 | -0.30 | -0.6% | 54.00 | 54.70 | 53.30 | 81,033 | |
| 54.20 | -0.90 | -1.6% | 54.80 | 55.00 | 54.20 | 49,739 | |
| 55.10 | -0.60 | -1.1% | 55.40 | 55.90 | 55.10 | 68,313 | |
| 55.70 | -0.20 | -0.4% | 56.00 | 56.00 | 55.20 | 61,704 | |
| 55.90 | +0.40 | +0.7% | 55.80 | 56.90 | 55.60 | 87,209 | |
| 55.50 | -0.40 | -0.7% | 56.00 | 56.00 | 54.50 | 135,101 | |
| 55.90 | -0.10 | -0.2% | 55.80 | 56.20 | 55.60 | 89,543 | |
| 56.00 | -0.80 | -1.4% | 56.60 | 56.90 | 55.90 | 79,319 | |
| 56.80 | +0.60 | +1.1% | 56.50 | 56.90 | 56.00 | 76,530 | |
| 56.20 | -0.50 | -0.9% | 56.60 | 56.80 | 55.90 | 95,369 | |
| 56.70 | +1.20 | +2.2% | 55.70 | 57.00 | 55.70 | 94,315 | |
| 55.50 | -0.40 | -0.7% | 55.20 | 55.50 | 54.90 | 84,643 | |
| 55.90 | +0.80 | +1.5% | 54.90 | 55.90 | 54.60 | 54,740 | |
| 55.10 | -0.40 | -0.7% | 55.90 | 55.90 | 54.50 | 91,592 |
Splits
2 splits since 2001 · SIX:BION · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 5-for-1 | Split | |
| 10-for-1 | Split |
- Ticker
- OTC:BBAGF
- Asset type
- Stock
- Sector
- Financials
- Industry
- Investment companies & funds
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Jul 24, 2026
BB Biotech AG publishes its interim report and revises its dividend policy
Latest earnings call · Feb 20, 2026
BB Biotech (SIX Swiss: BION) Q4 2025 Earnings Call
Replay and transcript
Latest news
BB Biotech AG publishes its interim report and revises its dividend policy
Jul 24, 2026
Closed 50.80 (+1.8%) on Jul 24, 2026
BB Biotech Q2 2026: Strong NAV outperformance driven by disciplined stock selection and portfolio positioning
Jul 24, 2026
Closed 50.80 (+1.8%) on Jul 24, 2026
Interim Report (BION2026 Q1 en)
Apr 24, 2026
Closed 44.95 (-2.5%) on Apr 24, 2026
BB Biotech AG publishes its interim report
Apr 24, 2026
Closed 44.95 (-2.5%) on Apr 24, 2026
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.25 per share
Mar 19, 2026
Closed 45.40 (+1.5%) on Mar 20, 2026
BB Biotech AG publishes its 2025 annual report
Feb 20, 2026
Closed 46.45 (+1.0%) on Feb 20, 2026
BB Biotech AG closes the 2025 fiscal year with a profit
Jan 23, 2026
Closed 49.50 (+0.3%) on Jan 23, 2026
BB Biotech: Preliminary full-year 2025 results and dividend proposal
Jan 23, 2026
Closed 49.50 (+0.3%) on Jan 23, 2026
BB Biotech AG on 6ix
- Sector
- Financials
- Industry
- Investment companies & funds
- News releases
- 8 in the last 12 months · 11 in all · newest Jul 24, 2026 · oldest 2025
- Calls
- 1 call with a replay · 1 with a transcript · latest Feb 20, 2026
Where BB Biotech AG is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| SIX Swiss:BION · Home listing | SIX Swiss | Switzerland | CHF |
| Xetra:BBZA | Xetra | Germany | EUR |
| gettex:BBZA | gettex | Germany | EUR |
| Tradegate:BBZA | Tradegate | Germany | EUR |
| Lang & Schwarz:A0NFN3 | Lang & Schwarz | Germany | EUR |
| Frankfurt:BBZA | Frankfurt | Germany | EUR |
| Aquis:BIONZ | Aquis | United Kingdom | CHF |
| LSIN:0JYO | LSIN | United Kingdom | CHF |
| LS Exchange:A0NFN3 | LS Exchange | Germany | EUR |
| BX Swiss:BBZA | BX Swiss | Switzerland | CHF |
| Dusseldorf:BBZA | Dusseldorf | Germany | EUR |
| VIE:BION | Vienna | Austria | EUR |
| Stuttgart:BBZA | Stuttgart | Germany | EUR |
| Turquoise:BIONZ | Turquoise | United Kingdom | CHF |
| Hamburg:BBZA | Hamburg | Germany | EUR |
| Hanover:BBZA | Hanover | Germany | EUR |
| Munich:BBZA | Munich | Germany | EUR |
| OTC:BBAGF · This page | OTC | United States | USD |
| Aquis:BBZAD | Aquis | United Kingdom | EUR |
| Aquis:BBZAD | Aquis | United Kingdom | EUR |
| Turquoise:BBZAD | Turquoise | United Kingdom | EUR |
Valuation
P/E 2.7× against a median of 13.2×: the lowest of 7 Investment companies & funds companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −394.8M CHF
- P/E
- 2.7×
- EV/sales
- −1.8×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.9×
- Gross margin
- 100.0%
- Operating margin
- 490.7%
- Net margin
- 490.6%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Investment companies & funds: the 10 companies nearest in size, of 321 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BB Biotech AG · SIX:BION | US$3.45B | −US$470.2M | 2.7× | −1.8× | n/a | 0.9× | 490.6% | 0.0× | n/a |
| Main Street Capital Corporation · NYSE:MAIN | US$5.17B | US$7.65B | 11.6× | 10.9× | 15.6× | 1.6× | 63.6% | 0.8× | 0.58 |
| E-L Financial Corporation Limited · TSX:ELF | US$4.53B | US$4.70B | 3.6× | 1.7× | n/a | 0.7× | 46.7% | 0.1× | 0.63 |
| Blue Owl Technology Finance Corp. · NYSE:OTF | US$4.07B | US$11.05B | 11.3× | 7.9× | 17.9× | 0.5× | 25.6% | 0.9× | 0.64 |
| Wendel SE · EURONEXT:MF | US$3.48B | US$8.06B | n/a | 0.9× | 5.2× | 1.0× | −1.9% | 1.8× | n/a |
| Pershing Square USA, Ltd. · NYSE:PSUS | US$3.38B | US$3.38B | n/a | n/a | n/a | 3,437× | n/a | 0.0× | 0.99 |
| Tata Investment Corporation Limited · NSE:TATAINVEST | US$3.18B | US$3.18B | 74.0× | 70.2× | 77.1× | 0.9× | 95.0% | 0.0× | n/a |
| Golub Capital BDC, Inc. · NASDAQ:GBDC | US$3.18B | US$7.32B | 33.3× | n/a | n/a | 0.9× | n/a | 1.2× | 0.38 |
| FS KKR Capital Corp. · NYSE:FSK | US$2.96B | US$9.02B | n/a | 10.0× | 11.5× | 0.6× | −57.5% | 1.3× | 0.67 |
| Caledonia Investments PLC · LSE:CLDN | US$2.60B | US$2.49B | 14.7× | 11.4× | 14.0× | 0.7× | 81.5% | 0.0× | n/a |
| Investco Holding A.S. · BIST:INVES | US$2.58B | US$2.49B | n/a | 169× | 524× | 4.3× | −54.5% | 0.0× | n/a |
| Median of the others | US$3.28B | US$6.01B | 13.2× | 10.5× | 15.6× | 0.9× | 36.1% | 0.5× | 0.64 |
Forecasts
Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 73.00 CHF · Analysts' mean
- EPS, year to Dec 2026
- -0.61 · 1 analyst
- Revenue, year to Dec 2026
- 1.28B · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Rachael Burri | Head Investor Relations |
| Christian Koch | Head BB Biotech Team |
| Kyle Rasbach | Head Research |
Board
| Director | Role |
|---|---|
| Thomas von Planta | Chairman |
| Mads Krogsgaard Thomsen | Vice-Chairman |
Events
- Next results
- Feb 19, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| BB Biotech (SIX Swiss: BION) Q4 2025 Earnings Call | Fri, Feb 20, 2026 · 4:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 23, 2026 · After close | +1.4% |
| Q2 2026 | Jul 24, 2026 · After close | +2.6% |
| Q1 2026 | Apr 24, 2026 · After close | +1.0% |
| Q4 2025 | Feb 20, 2026 · After close | +1.2% |
| Q3 2025 | Oct 24, 2025 · After close | +3.1% |
| Q2 2025 | Jul 25, 2025 · After close | +1.8% |
| Q1 2025 | Apr 25, 2025 · Before open | +1.8% |
| Q4 2024 | Feb 21, 2025 · Before open | +1.7% |
| Q3 2024 | Oct 25, 2024 · Before open | −3.9% |
| Q2 2024 | Jul 26, 2024 · Before open | +1.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 26, 2024 · Before open | −0.3% |
| Q4 2023 | Jan 19, 2024 · Before open | −0.8% |
| Q3 2023 | Oct 20, 2023 · Before open | −2.4% |
| Q2 2023 | Jul 21, 2023 · Before open | −2.5% |
| Q1 2023 | Apr 21, 2023 · Before open | −2.8% |
| Q4 2022 | Feb 20, 2023 · Before open | +0.2% |
| Q3 2022 | Oct 21, 2022 · Before open | +0.4% |
| Q2 2022 | Jul 22, 2022 · Before open | +0.5% |
| Q1 2022 | Apr 22, 2022 · Before open | −3.0% |
| Q4 2021 | Feb 18, 2022 · Before open | −1.4% |
Financials
Annual, in CHF
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.8M | 111.6M | 35.0K | -351.2M | -396.2M | 699.2M | 685.2M | -465.8M | 693.1M | -796.4M |
| Cost of revenue | 55.0K | 4.98M | 5.80M | 1.73M | 986.0K | 883.0K | 1.24M | 1.09M | 542.0K | 1.08M |
| Gross profit | 76.8M | 111.6M | 35.0K | -351.2M | -396.2M | 699.2M | 685.2M | -465.8M | 693.1M | -796.4M |
| Selling, general and administrative | 7.60M | 27.2M | 4.23M | 4.26M | 6.06M | 5.23M | 4.66M | 2.73M | 3.14M | 3.39M |
| Operating income | 586.8M | 84.4M | -29.9M | -356.0M | -404.7M | 691.2M | 677.5M | -470.2M | 688.1M | -800.9M |
| Depreciation and amortization | 90.0K | 166.7M | 314.3M | 343.6M | 206.3K | 171.9K | 40.6M | 688.1M | 27.8M | |
| EBITDA | 84.5M | 136.7M | -41.8M | -61.1M | 691.5M | 677.7M | -429.6M | 1.38B | -773.1M | |
| Interest expense | 443.0K | 4.98M | 5.80M | 1.73M | 986.0K | 883.0K | 1.24M | 1.09M | 542.0K | 1.08M |
| Income before tax | 578.2M | 76.0M | -206.5M | -357.8M | -404.7M | 691.2M | 677.5M | -471.3M | 687.6M | -802.0M |
| Income tax | 66.0K | 54.0K | 79.0K | 61.0K | 67.0K | 75.0K | 68.0K | 71.0K | 77.0K | 71.0K |
| Net income | 578.1M | 75.9M | -206.6M | -357.8M | -404.8M | 691.2M | 677.4M | -471.3M | 687.5M | -802.1M |
| Earnings per share, basic | 10.54 | 1.38 | -3.77 | -6.46 | -7.31 | 12.48 | 12.23 | -8.51 | 12.42 | -14.51 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 98.2M | 458.0K | 501.0K | 1.95M | 2.83M | 6.82M | 30.7M | 22.1M | 10.7M | 10.2M |
| Short-term investments | 1.20M | 2.41B | 2.63B | 3.04B | 3.64B | 3.95B | 3.52B | 3.06B | 3.62B | 3.20B |
| Receivables | 5.51M | 0 | 1.83M | 1.52M | 334.0K | 0 | 10.2M | |||
| Inventory | -2.64B | -3.96B | -3.06B | -3.22B | ||||||
| Current assets | 104.9M | 2.41B | 2.64B | 1.95M | 2.83M | 3.96B | 30.7M | 22.4M | 10.7M | 20.4M |
| Total assets | 2.79B | 2.41B | 2.64B | 3.05B | 3.64B | 3.96B | 3.55B | 3.09B | 3.64B | 3.23B |
| Accounts payable | 3.54M | 3.22M | 3.49M | 2.88M | ||||||
| Current liabilities | 121.1M | 16.7M | 367.3M | 360.6M | 75.6M | 3.54M | 3.22M | 3.49M | 2.88M | |
| Total debt | 117.5M | 304.9M | 363.0M | 355.0M | 63.0M | 150.0M | 185.0M | 95.0M | 205.0M | |
| Total liabilities | 6.97M | 121.1M | 313.9M | 367.3M | 355.0M | 63.0M | 161.6M | 202.3M | 99.1M | 223.2M |
| Shareholders' equity | 2.78B | 2.29B | 2.32B | 2.69B | 3.28B | 3.89B | 3.39B | 2.88B | 3.54B | 3.00B |
| Shares outstanding | 54.8M | 54.8M | 54.8M | 55.4M | 55.4M | 55.4M | 55.4M | 55.4M | 55.4M | 55.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 309.1M | 304.6M | 218.3M | -357.8M | -404.8M | 262.4M | 215.0M | -471.3M | 687.5M | -802.1M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | 309.1M | 304.6M | 218.3M | -357.8M | -404.8M | 262.4M | 215.0M | -471.3M | 687.5M | -802.1M |
| Cash from investing | 588.9M | 579.1M | -424.0M | 917.5M | ||||||
| Cash from financing | -203.2M | -305.2M | -220.2M | -233.3M | 91.8M | -284.5M | -205.2M | -93.9M | -263.0M | -126.8M |
| Dividends paid | -98.5M | -109.7M | -156.3M | -212.2M | -199.4M | -188.4M | -169.0M | -182.8M | -152.1M | -160.5M |
| Share buybacks | -5.04M | -3.13M | 0 | -27.3M | -9.46M | -8.26M | 0 | -19.1M | -54.2M | |
| Change in cash | 97.8M | -43.0K | -1.45M | -887.0K | -3.98M | -23.9M | 8.63M | 11.3M | 501.0K | -10.8M |
Cap table
Built by 6ix from BB Biotech AG’s releases
- Common shares
- 55,149,250
- Fully diluted
- 55,149,250
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 55,149,250 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 55,149,250 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christian Koch | Head BB Biotech Team · Since at least Jul 24, 2026 |
| Kyle Rasbach | Head Research · Since at least Apr 24, 2026 |
| Mads Krogsgaard Thomsen | Vice-Chairman · Since at least Apr 24, 2026 |
| Rachael Burri | Head Investor Relations · Since at least Apr 24, 2026 |
| Thomas von Planta | Chairman · Since at least Apr 24, 2026 |
Log in to ask 6ix AI your own questions about BB Biotech AG.